Journal of Women's Health Care
Open Access
ISSN: 2167-0420
ISSN: 2167-0420
Carl Morrisson
OmniSeq, USA
Roswell Park Comprehensive Cancer Center, USA
Posters & Accepted Abstracts: J Women's Health Care
Immune report card is a New York State CLEP approved assay and is designed to provide comprehensive factual information for clinicians to support the decision process around the use of immuno-therapeutics with an emphasis on CPIs. IRC provides this information by analyzing the host immune response and multiple immunotherapy biomarkers using several testing modes and integrates the results into a single report. Specifically, IRC uses five test modes (1) RNA-seq to semi-quantitatively measure transcript levels of 384 immune response (IR) genes. (2) DNA-seq to estimate mutational burden. (3) MSI-PCR to assess microsatellite instability. (4) Fluorescent in situ Hybridization (FISH) to detect copy number gain of PD-L1 and PD-L2. (5) Immunohistochemistry (IHC) to measure protein expression of PD-L1 in the context of an FDA-approved assay and also to provide the pattern of expression for this marker as well as for CD3 and CD8. To summarize, from a clinical perspective the evaluation of TCRS, TILS, MuB, MSI and PD-L1/2 copy number provide comprehensive results for physician decision making regarding potential response to checkpoint inhibition therapy in a single report. IRC provides the most complete profile of the cell-mediated immune response and potential antigens to drugs targeting the PD-1 and PD-L1 pathway by consolidating results of drug-target gene expression, immune cell infiltration, MSI and mutation burden into a single harmonized report available today.
E-mail: carl.morrison@omniseq.com